U.S. Warts Treatment Market – Industry Trends and Forecast to 2030

U.S. Warts Treatment Market Analysis and Size

It has been witnessed that approximately 20% of the population suffer from sexually transmitted infections (STI), and a total of 42.5 million people were infected with HPV in 2018 in the U.S. There are more than 60 types of HPV, some of which tend to cause warts on the skin. Presently, numerous research studies are taking place which is anticipated to create a cutting-edge advantage for different manufacturers to develop new and innovative and advanced warts treatment drugs which are anticipated to provide numerous other opportunities in the warts treatment market.

Data Bridge Market Research analyses a growth rate in the U.S. warts treatment market in the forecast period 2023-2030. The expected CAGR of U.S. warts treatment market is tend to be around 8.70% in the mentioned forecast period. The market value is USD 530.7 million in 2022 and it would grow upto USD 1034.3 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

U.S. Warts Treatment Market Scope and Segmentation

Market Definition

Warts treatment include salicyclic acid, cryotherapy or cantharidin. Warts are a kind of skin infection that is caused by the human papillomavirus (HPV). This infection causes rough, skin-coloured bumps to form on the skin. This viral infection is contagious. In majority of the cases, warts found on the skin are harmless and can disappear without treatment. Warts treatment aims to destroy the wart, stimulate an immune system response to fight the virus, or both.

U.S. Warts Treatment Market Dynamics

Drivers

• Rising Cases of Sexually Transmitted Infections (STI)

The growing prevalence of sexually transmitted infections (STIs) is anticipated to boost the market's growth. Approximately 68 million infections in 2018 (prevalence), and that 1 in 5 people in the U.S. have an STI. There were an estimated 67.6 million prevalent and 26.2 million incident STIs in the U.S. Furthermore, Chlamydia, genital herpes, trichomoniasis, and human papillomavirus comprised 97.6% of all prevalent and 93.1% of all incident STIs. Persons between the age group of 15 to 24 years comprise 18.6% of all prevalent infections; however, they comprise 45.5%  of all incident infections. Hence, these higher number of infections boost the market growth.

• Availability of Diverse Treatments for Warts

Several market players are primarily involved in launching new treatment platforms that are anticipated to increase the growth of the U.S. warts treatment market during the forecast period 2023-2030. For instance, GenieMD, a global provider of telemedicine services, launched their telemedicine app iVisit in 2019, enabling the diagnosis and treatment of patients for warts treatment through virtual visit with the physician.

Opportunities

• Increasing Prevalence of Cervical Cancer

The number of cervical cancer rates are more in many underdeveloped countries, where more than 80% of cervical cancer cases are diagnosed. As per the statistics of WHO, cervical cancer is the most prevalent type of malignancy in women and the second top cause of cancer-related death in this region, responsible for over 300,000 fatalities per year. This year, approximately 14,100 women in the U.S. will be diagnosed with invasive cervical cancer. There was around 604,127 women were diagnosed with cervical cancer in 2020. It is expected that 4,280 deaths from this disease will occur in the U.S. this year. This boosts the market growth.

• Increased Research and Development Activities

Increasing R&D in order to develop treatment for warts treatment is anticipated to increase the growth of the market during the forecast period. For instance, Verrica Pharmaceuticals Inc. and Torii Pharmaceutical Co., Ltd. entered into collaboration and license agreement to develop and commercialize product candidates, including VP-102, for a topical formulation of cantharidin for treating molluscum contagiosum and common warts in Japan in March 21. In October 2019, Novan enhanced its proprietary product pipeline for external genital warts by submitting request for a pre-investigational new drug (IND) application to the US FDA for new product candidate—SB207. Thus, all these developments increase the market growth.

 Restraints/Challenges

• Lack of Awareness About Warts and their Associated Treatment

Despite the increased prevalence rates of warts, the diagnosis rate and treatment options are still low. The low diagnostic rate of warts is because of the lack of awareness about the infection, which may hinder the warts treatment market growth. For instance, in 2018, the diagnosis rate of warts treatment in U.S. among girls aged 15 to 17 years, was reduced by 92%, compared to 2014. Additionally, existing treatment procedures are often painful and can have unfavorable outcomes such as scarring that often requires frequent visits. This results in a reduction in the diagnostic rate, which is likely to LIMIT the warts treatment market.

This U.S. warts treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the U.S. warts treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

U.S. Warts Treatment Market Scope

The U.S. warts treatment market is segmented on the basis of type, treatment, product, dosage form, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Common Warts (Verruca Vulgaris)
• Genital Warts
• Plantar Warts
• Flat Warts
• Filiform Warts
• Periungual Warts
• Others

Treatment

• Medication
• Therapy
• Laser Treatment
• Surgery
• Cantharidin
• Candida Antigen Shots
• Acupuncture
• Others

Product

• Prescription
• Over the Counter (OTC)

Dosage Form

• Creams
• Liquid
• Gels
• Injectable Solutions
• Pads
• Tape
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy  

Competitive Landscape and U.S. Warts Treatment Market Share Analysis

The U.S. warts treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to U.S. warts treatment market.

Key players operating in the U.S. warts treatment market include:

• Bausch Health Companies Inc (Canada)
• Merck & Co., Inc (U.S.)
• Taro Pharmaceutical Industries Ltd (Israel)
• CryoIQ (Sweden)
• GSK plc (U.K.)
• BioNTech SE (Germany)
• Serum Institute of India Pvt. Ltd (India)
• Fotona (U.S.)
• Orgenesis Inc (U.S.)
• Perrigo Company plc (Ireland)
• CryoSurgery, Inc (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• Nielsen Biosciences (U.S.)
• Verrica Pharmaceuticals (U.S.)
• Aclaris Therapeutics, Inc (U.S.)
• Nowarta Biopharma Inc. (U.S.)
• Novan, Inc. (U.S.)
• Vaxart (U.S.)

SKU-55024